

15th February 2016

PAGB response to Proton Pump Inhibitors PPI and dementia study

New research, published online by JAMA Neurology, has suggested that Proton Pump Inhibitors (PPI) *may* be associated with increased risk of dementia. The observational research draws on data from a German health insurer.

John Smith, PAGB Chief Executive, comments: “The authors of this study acknowledge that their findings do not prove a cause and effect relationship between PPI use and the incidence of dementia in the elderly and they have been unable to reflect *all* dementia risk factors in their research approach.

“From the summary it seems clear this study focuses specifically on PPIs in long-term prescription use whereas PPIs available over-the-counter are only intended for short term use for treating acute conditions. All over-the-counter medicines in the UK have been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) and are rigorously assessed for safety and efficacy. Once on the market, their safety is continually monitored in light of any emerging evidence.

“We would recommend those who may be concerned should always speak to their GP or pharmacist before taking any medicine.”

-ENDS-

Notes to editors:

PAGB (Proprietary Association of Great Britain) is the UK trade association representing manufacturers of branded over-the-counter medicines, self care medical devices and food supplements. www.pagb.co.uk

For further information, please contact Pegasus: Lauren Jones or Amy Simmons

01273 712000 / PAGB@thisispegasus.co.uk